NMS-03305293 is an experimental pill designed to block a DNA-repair enzyme in cancer cells. All four of its registered trials had closed by November 2026.
PARP1-selective, brain-penetrant inhibitor, also called NMS-293. All four registered studies are now listed as terminated (registry read on 18 November 2026); that does not establish comparative efficacy or approval, and none has posted results. The monotherapy study NCT04182516 stopped after 52 actual participants because the sponsor shifted towards combinations, explicitly not because of emerging safety or efficacy concerns. The combination studies have since closed too: with temozolomide in recurrent glioblastoma (NCT04910022, 80 participants, discontinued by the sponsor for reasons it says are not related to safety), with temozolomide in small cell lung cancer (NCT06931626, 5 participants) and with topotecan in ovarian cancer (NCT06930755, 1 participant); the sponsor calls the last two strategic decisions not based on the drug's safety or clinical data. No study of it is open.
PARP1-selective, brain-penetrant inhibitor, also called NMS-293. Connects to PARP.
1.NMS-03305293 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NMS-03305293" OR ABSTRACT:"NMS-03305293" OR TITLE:"NMS-293" OR ABSTRACT:"NMS-293" OR TITLE:"itareparib" OR ABSTRACT:"itareparib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NMS-03305293, not a curated reading list.
Shares PARP, Small-cell lung cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Small-cell lung cancer, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Small-cell lung cancer, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/